Showing results (61-70 of 89) with videos related to
Sort By:
Pageof 9
BMJ Open|December 19, 2019
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trialAlexis Jones, Patrick Muller, Caroline J Dore, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in c1q-deficient miceHelen Ferry, Paul K Potter, Tanya L Crockford, et al.Proceedings of the National Academy of Sciences of the United States of America|December 13, 2002
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in miceJeremy S Brown, Tracy Hussell, Sarah M Gilliland, et al.Annals of the Rheumatic Diseases|June 29, 2010
B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapyInmaculada de la Torre, Rita A Moura, Maria J Leandro, et al.Frontiers in Immunology|August 22, 2017
Tumor Necrosis Factor (TNF) Bioactivity at the Site of an Acute Cell-Mediated Immune Response Is Preserved in Rheumatoid Arthritis Patients Responding to Anti-TNF TherapyRachel Byng-Maddick, Carolin T Turner, Gabriele Pollara, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2011
Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cellsNatalie A Carter, Rita Vasconcellos, Elizabeth C Rosser, et al.Proceedings of the National Academy of Sciences of the United States of America|November 4, 2009
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritisGraham P Wright, Clare A Notley, Shao-An Xue, et al.Journal of Autoimmunity|April 9, 2016
B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigensGeraldine Cambridge, Maria J Leandro, Lauren J Lahey, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2009
Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr micePaul A Blair, Karina A Chavez-Rueda, Jamie G Evans, et al.Clinical Rheumatology|January 25, 2012
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidanceYee Chiu, Andrew J K Ostor, Anthony Hammond, et al.Pageof 9